Literature DB >> 7836932

Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes.

R F Wang1, P F Robbins, Y Kawakami, X Q Kang, S A Rosenberg.   

Abstract

The availability of antitumor cytotoxic T lymphocytes which can be generated from either peripheral blood lymphocytes after stimulation in vitro or tumor infiltrating lymphocytes (TIL) has made it possible to identify a number of melanoma antigens presented by major histocompatibility complex class I molecules. The present and previous studies indicated that TIL586 recognized an antigen expressed on most melanoma and normal melanocytes in the context of the HLA-A31 molecule. We report here the cloning of a cDNA that directs the expression of the shared melanoma antigen recognized by this TIL. The DNA sequence analysis revealed that the cDNA was almost identical to the gene encoding tyrosinase-related protein 1 or glycoprotein gp75 which was originally identified by serum antibodies in a patient with melanoma. The gene was found to be expressed only in melanoma, normal melanocyte cell lines, and retina, but not in other normal tissues tested. The gp75 antigen presented by HLA-A31 may therefore constitute a useful immune target for specific treatment of patients with melanoma, since both antibody- and T cell-mediated immune responses can be generated against this antigen.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7836932      PMCID: PMC2191858          DOI: 10.1084/jem.181.2.799

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  34 in total

1.  Vitiligo in patients with metastatic melanoma: a good prognostic sign.

Authors:  J J Nordlund; J M Kirkwood; B M Forget; G Milton; D M Albert; A B Lerner
Journal:  J Am Acad Dermatol       Date:  1983-11       Impact factor: 11.527

2.  Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy.

Authors:  P F Robbins; M el-Gamil; Y Kawakami; E Stevens; J R Yannelli; S A Rosenberg
Journal:  Cancer Res       Date:  1994-06-15       Impact factor: 12.701

3.  Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines.

Authors:  F M Marincola; P Shamamian; T B Simonis; A Abati; J Hackett; T O'Dea; P Fetsch; J Yannelli; N P Restifo; J J Mulé
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1994-07

4.  Prognostic significance of hypopigmentation in malignant melanoma.

Authors:  J C Bystryn; D Rigel; R J Friedman; A Kopf
Journal:  Arch Dermatol       Date:  1987-08

5.  Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.

Authors:  Y Kawakami; S Eliyahu; C H Delgado; P F Robbins; K Sakaguchi; E Appella; J R Yannelli; G J Adema; T Miki; S A Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-05       Impact factor: 11.205

6.  A new enzymatic function in the melanogenic pathway. The 5,6-dihydroxyindole-2-carboxylic acid oxidase activity of tyrosinase-related protein-1 (TRP1).

Authors:  C Jiménez-Cervantes; F Solano; T Kobayashi; K Urabe; V J Hearing; J A Lozano; J C García-Borrón
Journal:  J Biol Chem       Date:  1994-07-08       Impact factor: 5.157

7.  Production of stable cytolytic T-cell clones directed against autologous human melanoma.

Authors:  M Hérin; C Lemoine; P Weynants; F Vessière; A Van Pel; A Knuth; R Devos; T Boon
Journal:  Int J Cancer       Date:  1987-03-15       Impact factor: 7.396

8.  Molecular characterization of the melanocyte lineage-specific antigen gp100.

Authors:  G J Adema; A J de Boer; A M Vogel; W A Loenen; C G Figdor
Journal:  J Biol Chem       Date:  1994-08-05       Impact factor: 5.157

9.  Cancer antigens: immune recognition of self and altered self.

Authors:  A N Houghton
Journal:  J Exp Med       Date:  1994-07-01       Impact factor: 14.307

10.  A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.

Authors:  P G Coulie; V Brichard; A Van Pel; T Wölfel; J Schneider; C Traversari; S Mattei; E De Plaen; C Lurquin; J P Szikora; J C Renauld; T Boon
Journal:  J Exp Med       Date:  1994-07-01       Impact factor: 14.307

View more
  66 in total

1.  IFN-gamma enables cross-presentation of exogenous protein antigen in human Langerhans cells by potentiating maturation.

Authors:  Mitsutoshi Matsuo; Yasuhiro Nagata; Eiichi Sato; Djordje Atanackovic; Danila Valmori; Yao-Tseng Chen; Gerd Ritter; Ira Mellman; Lloyd J Old; Sacha Gnjatic
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-21       Impact factor: 11.205

2.  Induction of auto-logous human cytotoxic T lymphocytes (CTL) from peripheral blood against tumor cells.

Authors:  T Ohno
Journal:  Cytotechnology       Date:  1997-01       Impact factor: 2.058

Review 3.  The next wave of recombinant and synthetic anticancer vaccines.

Authors:  K R Irvine; N P Restifo
Journal:  Semin Cancer Biol       Date:  1995-12       Impact factor: 15.707

4.  Tumour infiltrating lymphocytes: insights into tumour immunology and potential therapeutic implications.

Authors:  K F Yoong; D H Adams
Journal:  Clin Mol Pathol       Date:  1996-10

5.  Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas.

Authors:  Y T Chen; E Stockert; A Jungbluth; S Tsang; K A Coplan; M J Scanlan; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

6.  Up-regulation of specific tyrosinase mRNAs in mouse melanomas with the c2j gene substituted for the wild-type tyrosinase allele: utilization in design of syngeneic immunotherapy models.

Authors:  N Le Fur; W K Silvers; S R Kelsall; B Mintz
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

Review 7.  Cytolytic T lymphocyte responses of cancer patients to tumor-associated antigens.

Authors:  P Romero
Journal:  Springer Semin Immunopathol       Date:  1996

Review 8.  Exploiting the curative potential of adoptive T-cell therapy for cancer.

Authors:  Christian S Hinrichs; Steven A Rosenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

9.  Melanoma progression despite infiltration by in vivo-primed TRP-2-specific T cells.

Authors:  Vinod Singh; Qingyong Ji; Lionel Feigenbaum; Robert M Leighty; Arthur A Hurwitz
Journal:  J Immunother       Date:  2009 Feb-Mar       Impact factor: 4.456

10.  Changes in expression of putative antigens encoded by pigment genes in mouse melanomas at different stages of malignant progression.

Authors:  S J Orlow; V J Hearing; C Sakai; K Urabe; B K Zhou; W K Silvers; B Mintz
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.